BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251109
DTEND;VALUE=DATE:20251112
DTSTAMP:20260515T035143
CREATED:20250613T091742Z
LAST-MODIFIED:20250613T091907Z
UID:41257-1762646400-1762905599@www.pharmajournalist.com
SUMMARY:8th Neuropsychiatric Drug Development Summit
DESCRIPTION:Industry’s Flagship Forum Capturing Advancements Across Discovery\, Preclinical\, Translational\, Clinical & Regulatory Development of Innovative Neuropsychiatric Therapeutics \nUniting 150+ discovery\, preclinical\, translational\, clinical\, and regulatory leaders\, the 8th Neuropsychiatric Drug Development Summit returns to provide you with an unrivaled opportunity to stay attuned to the latest progress while tackling industry’s most pressing challenges across a wide spectrum of mental health indications. \n \nRecognized by key leaders as the “ideal size”\, offering a “targeted audience” perfect for meaningful networking and collaboration\, join thought leaders from Bristol Myers Squibb\, AbbVie\, Otsuka\, Johnson & Johnson\, Biogen\, Lundbeck\, Delix Therapeutics\, Boehringer Ingelheim\, and many more this September to revitalize the mental health drug development landscape. \nOver the 3 day agenda\, you’ll engage in deep-dive interactive workshops\, roundtable discussions\, data-driven presentations and structured networking activities to foster collaboration and gain the latest insights to truly advance your pipeline of next generation neuropsychiatric therapeutics. \nOur attendees span discovery\, in vivo pharmacology\, translational medicine\, clinical development\, medical\, regulatory affairs\, academics\, venture capitalists\, and solution providers\, ensuring that whatever part you play in transforming the mental health treatment and therapeutic landscape\, you are surrounded by peers with the knowledge and capacity to support you. \nWhen you join the Neuropsychiatric Drug Development Summit you can expect to: \n\nDecipher the journey to ‘precision psychiatry’ through investigating the most progressive advancements in EEG and fluid-based markers\nDiscover innovative strategies to control placebo responses and bridge the translational gap to effectively analyze phenotypic behavior preclinically\nInvestigate the efficacy of standalone psychedelics vs when applied in conjunction with psychotherapy\, and explore groundbreaking progress in novel non-hallucinogenic neuroplastogens\nReview the latest advancements in new targets and mechanisms\, including moving beyond atypical antidepressants and antipsychotics\, to truly transform patient burdens\n\nPlus\, all new for 2025 is the EEG Focus Day which will support your efforts in utilizing EEG as a comprehensive and translational tool to guide your program through end-to-end development\, and the new Investor’s Panel which will explore the catalysts driving deal-making momentum in the current neuropsychiatric and mental health R&D landscape. \nSo\, what are you waiting for? Learn more about the summit today and explore the 40+ leading experts presenting at this year’s meeting\, the array of sessions and bespoke workshops designed to support you\, and the companies attending to advance neuropsychiatric therapeutics. \nView the brochure now for all this and more: https://ter.li/g4f9aj
URL:http://www.pharmajournalist.com/event/8th-neuropsychiatric-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251110
DTEND;VALUE=DATE:20251112
DTSTAMP:20260515T035143
CREATED:20250610T104455Z
LAST-MODIFIED:20250610T111651Z
UID:41230-1762732800-1762905599@www.pharmajournalist.com
SUMMARY:Transdermal and Microneedle Drug Delivery
DESCRIPTION:Have you considered how microneedle drug delivery systems could revolutionise the future of vaccine and drug administration? \nThis November\, join SAE Media’s 4th Annual Transdermal and Microneedle Drug Delivery Conference. Engage with leading drug development and delivery experts in a dynamic\, expert-led environment. Connect with forward-thinking innovators to explore cutting-edge case studies\, breakthrough vaccine and therapeutic applications\, and the evolving capabilities of transdermal and microneedle technologies. Transdermal and microneedle patches hold the potential to ‘go beyond the needle’ and transform pharmaceutical development—offering enhanced accessibility and long-term delivery solutions. With applications ranging from improved vaccine distribution to advanced diagnostics\, these technologies are poised to reshape healthcare by increasing efficacy and expanding global access to life-changing treatments. \nTo know more click here.
URL:http://www.pharmajournalist.com/event/transdermal-and-microneedle-drug-delivery-2025/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:marketingteamlondon@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251110
DTEND;VALUE=DATE:20251113
DTSTAMP:20260515T035143
CREATED:20250703T134927Z
LAST-MODIFIED:20250703T134927Z
UID:41451-1762732800-1762991999@www.pharmajournalist.com
SUMMARY:7th Targeted Radiopharmaceuticals Summit Europe
DESCRIPTION:7th Targeted Radiopharmaceuticals Summit Europe \n10–12 November 2025 | Amsterdam \nTranslating Novel Radiopharmaceutical Therapies to Transform the Medical Future \n \nNow in its seventh year\, the Targeted Radiopharmaceuticals Summit Europe returns to Amsterdam to bring together over 200 leaders in radiopharmaceutical therapy development. Designed to establish radiopharmaceuticals as a core pillar of oncology\, this event is essential for professionals working across discovery\, clinical development\, and manufacturing. \nHighlights of the 2025 Program: \nMore than 45 expert speakers from leading companies including Bayer\, AstraZeneca\, Novartis\, Telix Pharmaceuticals\, and more\nIntroduction of a third content track\, covering:\nDiscovery & Preclinical\nTranslational & Clinical\nCMC & Sourcing\nSix in-depth workshops on key challenges including radiopharmaceutical design\, dosimetry translation\, and isotope supply \nKey Speakers: \nThomas Birger Eden-Jensen\, Head\, External Supply Management TRP\, Bayer\nMark Fielding\, Director\, CMC\, Regulatory Affairs\, TRP\, AstraZeneca NEW SPEAKER\nIsabel Jaco\, Group Leader\, RLT Drug Discovery\, Novartis NEW SPEAKER\nSandra Uhlenbroich\, Director\, Discovery\, Bicycle Therapeutics NEW SPEAKER\nFrederic Fantino\, Global Medical Affairs EMEA\, Telix Pharmaceuticals NEW SPEAKER\nThijs Spoor\, Chief Executive Officer\, Perspective Therapeutics NEW SPEAKER\nSigal Kalmanson\, Chief Executive Officer\, Starget Pharma \nTopics Include: \nNovel target discovery\, including SSTR3 and FAP\nIsotope selection and supply chain resilience\nTranslating dosimetry into clinical studies\nFirst-in-human study design and Phase 0 considerations\nScalable and compliant manufacturing strategies \nThis is the most comprehensive European agenda for targeted radiopharmaceuticals to date\, built to accelerate asset development and address the sector’s most pressing challenges. \nView the full program: https://ter.li/gowcuf \nHyperlink – https://ter.li/gowcuf
URL:http://www.pharmajournalist.com/event/7th-targeted-radiopharmaceuticals-summit-europe/
LOCATION:Mövenpick Hotel Amsterdam City Centre\, Piet Heinkade 11\, Amsterdam\, 1019 BR\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251111
DTEND;VALUE=DATE:20251114
DTSTAMP:20260515T035143
CREATED:20250829T114659Z
LAST-MODIFIED:20250829T114659Z
UID:41812-1762819200-1763078399@www.pharmajournalist.com
SUMMARY:7th TIL Therapies Summit
DESCRIPTION:Now in its seventh year\, the TIL Therapies Summit returns as the leading event dedicated to advancing tumor-infiltrating lymphocytes (TIL) therapies. Taking place November 11–13\, 2025\, in Boston (MA)\, this summit unites global experts across biopharma\, academia\, clinical practice\, and manufacturing to accelerate the development and commercialization of next-generation TIL treatments. \nFollowing the first-ever FDA approval of a TIL therapy in the U.S.\, and with regulatory decisions pending in Canada and Europe\, the field is at a pivotal inflection point. The 7th TIL Therapies Summit offers a timely platform to explore how optimized TIL selection\, engineering\, and manufacturing can unlock scalable\, potent treatments for solid tumors beyond melanoma. \nThe program is designed to tackle the most pressing challenges in TIL development\, including: \n\nEngineering TILs for improved persistence\, potency\, and specificity\nManufacturing innovations in closed systems to speed-up turnaround\, and reduce IL-2 dependency\nClinical trial design and patient access strategies\nBiomarker discovery and potency assay development\nReal-world implementation and patient/provider perspectives\n\nWith 28+ expert speakers\, 50+ attendees\, and 8 hours of dedicated networking\, the summit fosters a collaborative environment for sharing cutting-edge science\, operational insights\, and lived experiences. Attendees will hear from leading voices including: \n\nInge Jedema\, Netherlands Cancer Institute\nJingwei Sun\, Grit Biotechnology\nMadan Jagasia\, Obsidian Therapeutics\nMicah Benson\, KSQ Therapeutics\nMichael Lotze\, University of Pittsburgh\nRoda Amaria\, MD Anderson Cancer Center\n\nYou can see who else is speaking in this year’s program: https://ter.li/i4a730 \nWhether you’re preparing for your first clinical trial\, scaling manufacturing\, or navigating regulatory pathways\, this summit delivers actionable insights for every stage of the TIL pipeline. Two new tracks focused on R&D and CMC ensure that both scientific and operational teams gain maximum value. \nUnlike broader cell therapy events\, the TIL Therapies Summit offers a focused\, intimate setting where attendees can engage in meaningful dialogue\, build lasting partnerships\, and stay ahead of the curve in this rapidly evolving space. \nIf you’re committed to transforming the treatment landscape for solid tumors\, the 7th TIL Therapies Summit is your must-attend event for 2025. \nFind out more here: https://ter.li/nfdnks
URL:http://www.pharmajournalist.com/event/7th-til-therapies-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR